Brief: Innate Pharma To Stop Exploring Avdoralimab in Covid-19

Innate Pharma SA

06/07/2021 06:15

July 6 (Reuters) - INNATE PHARMA SA  IPH.PA :
    * UPDATE ON AVDORALIMAB PHASE 2 FORCE TRIAL IN COVID-19
PATIENTS
WITH SEVERE PNEUMONIA
    * COMPANY WILL STOP EXPLORING AVDORALIMAB IN COVID-19
    * INVESTIGATOR-SPONSORED AVDORALIMAB CLINICAL TRIAL IN
INFLAMMATION WILL CONTINUE
    * INVESTIGATOR-SPONSORED FORCE TRIAL DID NOT MEET PRIMARY
ENDPOINTS
    * TODAY'S RESULTS DO NOT IMPACT INVESTIGATOR-SPONSORED,
PHASE 2
TRIAL OF AVDORALIMAB IN BULLOUS PEMPHIGOID
    * MORE THAN 100 PATIENTS HAVE BEEN TREATED WITH AVDORALIMAB
IN
INFLAMMATION AND ONCOLOGY CLINICAL TRIALS WITH NO NEW OR
UNEXPECTED SAFETY SIGNALS OBSERVED
    * INVESTIGATORS AND INDEPENDENT DATA MONITORING COMMITTEE
OBSERVED
SLIGHTLY HIGHER DEATHS IN TREATMENT ARM COMPARED TO PLACEBO
WITHOUT CAUSALITY BEING ESTABLISHED

Source text for Eikon:  ID:nGNE7YfL4h 
Further company coverage:  IPH.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))